After starting Vascepa (generic name: icosapent ethyl), the time it takes to notice improvements can vary depending on the individual and the specific condition being treated. Vascepa is a prescription medication primarily used to reduce triglyceride levels in adults with severe (≥500 mg/dL) hypertriglyceridemia [1].
Clinical studies have shown that Vascepa can lower triglyceride levels by 20-30% when taken as directed (typically 4 grams per day) [1]. However, it is essential to note that improvements in triglyceride levels might not necessarily result in immediate noticeable changes in how an individual feels.
In a study called the REDUCE-IT trial, Vascepa demonstrated a significant reduction in cardiovascular events in patients with elevated triglycerides and either established cardiovascular disease or diabetes and other risk factors [2]. The trial showed a 25% relative risk reduction in major adverse cardiovascular events (MACE), including cardiovascular death, non-fatal heart attacks, non-fatal strokes, and unstable angina requiring hospitalization [2].
Therefore, while improvements in triglyceride levels might not be immediately noticeable, long-term benefits in terms of reduced cardiovascular risk may be achieved with consistent use of Vascepa as prescribed by a healthcare professional.
It is crucial to follow up with a healthcare provider for regular monitoring and to report any new or worsening symptoms.
Sources:
1. Vascepa (icosapent ethyl) capsules, for oral use. Full Prescribing Information. Amarin Pharma Inc.; 2021. Available from: <https://www.vascepa.com/pdf/VASCEPA-PI-MG-2021.pdf>.
2. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi: 10.1056/NEJMoa1812797. Available from: <https://www.nejm.org/doi/full/10.1056/NEJMoa1812797>.
3. DrugPatentWatch. Vascepa (icosapent ethyl) [Internet]. DrugPatentWatch; 2021. Available from: <https://www.drugpatentwatch.com/drugs/vascepa>.